NEW YORK (TheStreet) -- CHANGE IN RATINGS
Cisco (CSCO) was initiated with a sell rating at Citigroup. $18 price target. Expecting share loss ahead, Citigroup said.
Ciena (CIEN) was initiated with a neutral rating at Citigroup. $25 price target. Strong tailwinds likely to calm down after string of good quarters, Citigroup said.
Entergy (ETR) was downgraded at Deutsche Bank to hold from buy. $64 price target. Fed taper could weigh on the group, Deutsche Bank said.
WR Grace (GRA) was downgraded at Robert Baird to neutral from outperform. $100 price target. Stock is already pricing in expected near-term catalysts, Robert Baird said.
Labcorp (LH) was downgraded at Canaccord Genuity to hold. $91 price target. Company is guiding toward lower earnings, Canaccord Genuity said.
3M (MMM) was upgraded at Nomura to buy. $150 price target. Organic growth is accelerating and the company is allocating capital better, Nomura said.
MeadWestvaco (MWV) was downgraded at BMO Capital to underperform from market perform. Valuation call, based on a $35.50 price target, BMO Capital said.
Owens Illinois (OI) was downgraded at Goldman Sachs to neutral from buy. Valuation call, based on a $35 price target, Goldman said.
Children's Place (PLCE) was upgraded at FBR Capital Markets to outperform from market perform. $62 price target. Company should benefit from cold weather and easy comps in 2014, FBR Capital Markets said.
Dentsply (XRAY) was upgraded at Goldman Sachs to buy. $56 price target. Company has several earnings growth drivers, Goldman said.
Stock Comments / EPS Changes
CVS Caremark price target and estimates were raised at Credit Suisse. A new generic deal should drive growth, Credit Suisse said. $75 price target and outperform rating.
CVS Caremark price target and estimates were raised by UBS. A joint venture generic drug procurement deal between CVS and Cardinal Health lifted numbers, said UBS. $77 price target and buy rating.
Forest Labs (FRX) estimates and price target were raised by BMO Capital. The company's cost-cutting and plans for stock buybacks drove the new rating, said BMO. $49 price target and market perform rating.
[Read: More of Us Are Paying More for Rent]
Labcorp price target, EPS estimates were lowered at UBS. Pressured by weak utilization environment, government pricing pressure, slow initial enrollment on ACA exchanges and continued increases in deductibles and co-pays, UBS said. $93 price target and neutral rating.
Stanley Black & Decker (SWK) price target was lowered at UBS. Driven by weaker security margins, lower organic growth, and incremental tax headwinds, UBS said. $89 price target and buy rating.